March 6, 2020
MSD’s anti-PD-1 antibody Keytruda (pembrolizumab) continues to grab the top spot in the Japanese drug sales ranking in February, netting sales of 10.9 billion yen on an NHI price basis, according to a monthly snapshot report released by market research...read more